Exenatide once monthly: Additional Phase II data

Additional data from an open-label, U.S. Phase II trial in 121 Type II diabetics showed that 50%, 57% and 70% of patients receiving 5, 8 and 11 mg subcutaneous exenatide once monthly, respectively, achieved an HbA1c of <7% at week 20 vs. 48% for 2 mg subcutaneous Bydureon exenatide once weekly. Additionally, low-, mid- and high-dose exenatide once monthly reduced mean FPG from baseline to week 20 by 25, 30 and 49 mg/dL, respectively, vs. 34 mg/dL for Bydureon. The trial enrolled patients with Type II diabetes who were not achieving adequate HbA1c control with diet and exercise alone or in conjunction with a stable regimen of metformin and/or Actos pioglitazone from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502, Osaka, Japan). Data were presented at the American Diabetes Association meeting in San Diego. ...